The relationship of markers of early and late lymphocytes activation with the efficiency of neoadjuvant chemotherapy in triple negative breast cancer patients

Abstract

Introduction. Determination of reliable predictive and prognostic biomarkers is essential, both for assessing the clinical course of cancer and for the development of adequate treatment methods.

The aim of the study is to determine the relationship between CD3+CD19 and CD3+CD4+-T-cells, CD3CD19+-B-cells, activated CD25+-, CD4+CD25+-, HLA-DR+-, CD3+HLA-DR+-, CD3-HLA-DR+-cells and CD16+CD56+Perforin+ peripheral blood lymphocytes (PBL) with immediate and long term results of neoadjuvant chemotherapy (NAСT) with paclitaxel and cisplatin in patients with TN BC.

Material and methods. The study included 76 patients aged 26 to 76 years. The observation period was 66.9 months. Using multivariate cytometric analysis, the relationship between the initial (before chemotherapy) amount of CD3+CD19, CD3+CD4+, CD3CD19+, CD25+, CD4+CD25+, HLA-DR+, CD3+HLA-DR+, CD3-HLA-DR+, CD16+CD56+Perforin+ lymphocytes stage of disease, degree of therapeutic pathomorphosis (TP), disease progression (DP), overall (OS) and relapse-free survival (DFS) of patients was investigated.

Results. An increase in the initial number of CD25+- и CD4+CD25+-lymphocytes was associated with an increase, and HLA-DR+- and CD3-HLA-DR+-cells with a decrease in DFS and OS in patients compared with patients in whom these parameters were reduced. An increase in the initial number of HLA-DR+- and CD3+HLA-DR+-cells was associated with later stages of the disease, and an increase in the percentage of CD3-HLA-DR+-lymphocytes was combined with a low level of TP.

Conclusion. Populations of CD25+- и CD4+CD25+-PBLs may be possible positive predictive factors in patients with TN BC receiving NACT with cisplatin and paclitaxel. It can be assumed that NAH with paclitaxel and cisplatin will be less effective in patients with stage IIIII breast cancer who have an «increased» number of HLA-DR+- and CD3-HLA-DR+-lymphocytes before treatment than in patients with a decrease in the initial number of these cells.

Keywords:triple negative breast cancer; subsets of peripheral blood lymphocytes; neoadjuvant chemotherapy; stage of the disease, degree of therapeutic pathomorphosis of the tumor; disease progression, disease-free survival; overall survival

For citation: Kadagidze Z.G., Chertkova A.I., Zabotina T.N., Gordeeva O.O., Borunova A.A., Shoua E.K., Zakharova E.N., Tabakov D.V. The relationship of markers of early and late lymphocytes activation with the effectiveness of neoadjuvant chemotherapy in patients with triple negative breast cancer with the efficiency of neoadjuvant chemotherapy in triple negative breast cancer patients. Immunologiya. 2021; 42 (2): 112-24. DOI: https://doi.org/10.33029/0206-4952-2021-42-2-112-124 (in Russian)

Funding. The study was performed with the financial support of the Ministry of Health of Russian Federation in the framework of research N ААА-А-А19-119022090028-6.

Conflict of interests. The authors declare no conflict of interests.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»